

May 29, 2017

The Manager- Listing
BSE Limited
Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing
National Stock Exchange of India Limited
Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra -Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Sub: AstraZeneca Pharma India Limited receives import and market permission in Form 45 (Marketing Authorization) from Drug Controller General of India (DCGI) for Osimertinib Tablet 40 mg and 80 mg.

This is to inform that AstraZeneca Pharma India Limited has received import and market permission in Form 45 (Marketing Authorization) from the Drug Controller General of India for Osimertinib Tablet 40 mg and 80 mg.

The receipt of this import and market permission paves way for the launch of Osimertinib Tablets (Tagrisso™) in India, subject to the receipt of other related statutory approvals and licenses.

Osimertinib (Tagrisso™) is the product of AstraZeneca group and has been approved in over 45 countries, including US, EU, Japan, China and other Asian countries.

Osimertinib (Tagrisso™) is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an appropriate test, whose disease has progressed on or after EGFR TKI therapy.

Osimertinib (Tagrisso™) is the first-in-class oral medication for advanced EFGR T790M mutation positive Non-Small Cell Lung Cancer.

Kindly take the same on record.

For AstraZeneca Pharma India Limited



Pratap Rudra
Company Secretary & Legal Counsel